Apnimed to Present at the Oppenheimer 31st Annual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that the Company’s management team will participate in the Oppenheimer 31st Annual Healthcare Conference, held virtually March 16-18, 2021. Apnimed’s presentation is scheduled for Wednesday, March 17th from 3:50 – 4:20 pm (ET).
Webcast Link:
A live webcast of Apnimed’s session will be available on the Events section of the Company's investor website at https://apnimed.com/events/ or can be accessed via the following link:
A replay of the presentation will be archived on Apnimed's investor website.
About Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) is one of the most common and serious sleep disorders and is estimated to affect more than 25 million Americans, though underdiagnosis continues to be a serious problem. OSA is characterized by partial or complete upper airway closure that occurs during sleep, which often leads to poor sleep, and in the long-term has been shown to exacerbate hypertension, diabetes, cardiovascular disease, strokes, and lead to early mortality. Additionally, OSA can impair work productivity, reduce functional ability, and lower quality of life.
Sleep-related muscular relaxation driven by the central nervous system is the key neurologic issue leading to OSA. In patients with OSA, sleep onset leads to a reduction in neuromuscular control of the upper airway and a corresponding relaxation of the upper airway and tongue muscles. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but many patients are dissatisfied with these mechanical nighttime devices and fewer than half are compliant long-term, leaving a significant population untreated, undertreated and at risk.
About AD109
Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep. AD109 is a first-in-class, oral pharmaceutical combination dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (NRI) with a low dose of our novel NCE selective antimuscarinic. The investigational drug is designed to be safe, effective, and convenient, addressing the key limitations of the current standard of care treatments.
About Apnimed
Apnimed is a clinical-stage company working to transform the treatment of sleep apnea based on a simple idea – patients will benefit from safe and effective oral drug treatment. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. To learn more visit Apnimed.com or follow the company on LinkedIn and Twitter.
Contacts
Media:
Courtney Heath
ScientPR
courtney@scientpr.com
617-872-2462
Investors:
Elizabeth Woo
Kendall IR
ewoo@kendallir.com
617-733-2165
Editor Details
-
Company:
- Businesswire
